stockrowLakefront Biotherapeutics - Sponsored ADR
LKFT Healthcare Biotechnology
Lakefront Biotherapeutics - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.3 billion, up 321.9% from fiscal 2024.
- Revenue
- −95.4%
- EPS
- +198.9%
- Free cash flow
- +18.2%
Quarter to June 2026, against a year earlier
Follow LKFT
Alert me
Lakefront Biotherapeutics - Sponsored ADR (LKFT) Free cash flow margin
Lakefront Biotherapeutics - Sponsored ADR's free cash flow margin over the twelve months to 30 June 2026 was 0.00%, up 24.4 percentage points from fiscal 2025 (−24.4%). Over the past ten years it has ranged from −200.0% (fiscal 2015) to 353.1% (fiscal 2019); the current reading is higher than 82% of that period. That is in line with the Biotechnology industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Embed this chart
Annual newest first
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2025 | −24.4% | 121.54 |
| FY2024 | −145.9% | 30.49 |
| FY2023 | −176.4% | (70.15) |
| FY2022 | −106.2% | 9.62 |
| FY2021 | −115.9% | (18.05) |
| FY2020 | −97.8% | (450.85) |
| FY2019 | 353.1% | 402.19 |
| FY2018 | −49.1% | 49.92 |
| FY2017 | −99.1% | (253.82) |
| FY2016 | 154.8% | 354.74 |
Against its own ten years
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| SEPN Septerna, Inc. compare | 118.9% |
| AUPH Aurinia Pharmaceuticals Inc compare | 55.0% |
| VCEL Vericel Corporation compare | 17.9% |
| IMNM Immunome, Inc. compare | 0.00% |
| VERA Vera Therapeutics, Inc. compare | 0.00% |
| LKFT Lakefront Biotherapeutics - Sponsored ADR | 0.00% |
| BHVN Biohaven Ltd. compare | 0.00% |
| PVLA Palvella Therapeutics, Inc. compare | 0.00% |
| ZYME Zymeworks Inc. compare | −324.7% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue
More on LKFT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement